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Abstract Two large-scale phenotyping efforts, the Euro-
pean Mouse Disease Clinic (EUMODIC) and the Wellcome
Trust Sanger Institute Mouse Genetics Project (SANGER-
MGP), started during the late 2000s with the aim to deliver a
comprehensive assessment of phenotypes or to screen for
robust indicators of diseases in mouse mutants. They both
took advantage of available mouse mutant lines but pre-
dominantly of the embryonic stem (ES) cells resources
derived from the European Conditional Mouse Mutagenesis
programme (EUCOMM) and the Knockout Mouse Project
(KOMP) to produce and study 799 mouse models that were
systematically analysed with a comprehensive set of phys-
iological and behavioural paradigms. They captured more
than 400 variables and an additional panel of metadata
describing the conditions of the tests. All the data are now
available through EuroPhenome database (www.euro
phenome.org) and the WTSI mouse portal (http://www.
sanger.ac.uk/mouseportal/), and the corresponding mouse
lines are available through the European Mouse Mutant
Archive (EMMA), the International Knockout Mouse
Consortium (IKMC), or the Knockout Mouse Project
(KOMP) Repository. Overall conclusions from both studies
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converged, with at least one phenotype scored in at least
80 % of the mutant lines. In addition, 57 % of the lines were
viable, 13 % subviable, 30 % embryonic lethal, and 7 %
displayed fertility impairments. These efforts provide an
important underpinning for a future global programme that
will undertake the complete functional annotation of the
mammalian genome in the mouse model.
Introduction
Sequencing a genome will soon be routinely achieved in
less than a week. Nevertheless, despite advances in our
ability to decipher and annotate genomes, our under-
standing of the functions of genes is limited. With its
highly developed genetics, the mouse has become the
mammalian model of choice for the study of gene function
(Collins et al. 2007). Almost one third of the known mouse
genes representing predictive forms of a coding sequence
are still not well annotated for functions. A third of mouse
genes possess some functional annotation, reflecting the
analysis of point mutations, though not always related to
loss-of-function effects. The analysis of the remaining third
has depended on the specific interests and expertise of
investigators and not, in most cases, on a comprehensive
phenotyping approach.
Several initiatives have combined effort over the last
few years to attempt a systematic and comprehensive
functional assessment of all mouse genes. Based on a
roadmap discussed in 2004 (Austin et al. 2004; Auwerx
et al. 2004), a series of mouse programmes have been set
up with the goal of generating a compendium of mutations
in embryonic stem (ES) cells, to produce the mutant mouse
lines, to phenotype them, and to make these new resources
available to the scientific community (Table 1). The first
element of this vision, the construction of a mutant ES cell
resource for every mouse gene, has led to the development
of the International Knock-out Mouse Consortium (IKMC),
which brings together the various programmes funded
in Europe (European Conditional Mouse Mutagenesis,
EUCOMM), the US (Knock-Out Mouse Project, KOMP,
and Texas A&M Institute for Genomic Medicine, TIGM),
Canada (North American Conditional Mouse Mutagen-
esis Project, NorCOMM), and Asia (The Asian Mouse
Mutagenesis and Resource Association, AMMRA). This
consortium began its work in 2006 and aims to generate a
complete resource of reporter-targeted alleles in C57BL/
6 N (B6 N) mouse ES cells. The C57BL/6 genetic back-
ground is considered to be the ideal background for large-
scale phenotyping with a highly characterized genome and
one of the best characterised inbred strains, although
resistant to certain complex traits such as tumour forma-
tion. The design and construction of the conditional tar-
geting constructs was performed through a well-defined
pipeline (Skarnes et al. 2011).
The European Mouse Clinics organised the EUMORPHIA
programme in order to develop new mouse phenotyping
approaches from 2002 to 2006. This led to the definition of the
European Mouse Phenotyping Resource of Standardised
Screens (EMPRESS), with standard operating procedures
(SOPs) for mouse functional analysis (Brown et al. 2005).
Using the knowledge gained and the acquired experience of
Table 1 List of the consortia connected to the mouse large-scale phenotyping initiatives
Consortium Website
The European Conditional Mouse Mutagenesis Programme (EUCOMM) www.eucomm.org
The EUCOMMTools: Tools for Functional Annotation of the Mouse
Genome (EUCOMMTools)
www.eucommtools.org
The European Mouse Phenotyping Resource of Standardised Screens (EMPRESS) www.empress.har.mrc.ac.uk
The European Union Mouse Research for Public Health and Industrial
Applications (EUMORPHIA)
www.eumorphia.org
The European Mouse Disease Clinic (EUMODIC) www.EUMODIC.org
The EuroPhenome Mouse Phenotyping Resource www.europhenome.org
The European Mouse Mutant Archive (EMMA) www.emmanet.org
The European Infrastructure for Phenotyping and Archiving of model mammalian
genomes (INFRAFRONTIER)
www.infrafrontier.eu
The International Knockout Mouse Consortium (IKMC) www.knockoutmouse.org
The International Mouse Phenotyping Consortium (IMPC) www.mousephenotype.org
The Knockout Mouse Project (KOMP) www.komp.org
The Knockout Mouse Phenotyping Programme (KOMP2) http://commonfund.nih.gov/KOMP2/
The Wellcome Trust Sanger Institute Mouse Genetics Project (SANGER-MGP) http://www.sanger.ac.uk/mouseportal/
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large-scale chemical mutagenesis programmes (Hrabe´ de
Angelis et al. 2000; Nolan et al. 2000), the European Mouse
Disease Clinic (EUMODIC) brought together four European
mouse clinics, the MRC in Harwell (UK), the German Mouse
Clinic in Munich (Gailus-Durner et al. 2005), the Institut
Clinique de la Souris (ICS) in Strasbourg-Illkirch (France),
and the Wellcome Trust Sanger Institute in Hinxton, which
also launched the Mouse Genetics Project (SANGER-MGP)
to produce large-scale standardized mouse phenotyping data.
With the EUCOMM programme commencing a year before
to produce mutant ES cells in up to 8,000 mouse genes, it was
a perfect opportunity to take advantage of the targeted ES
cells generated by this consortium to generate mouse mutant
lines and to phenotype them.
After four years of activity both programmes together
produced 665 new mouse lines and the number continues
to increase. The high-throughput production and pheno-
typing assist in deciphering the function of genes with no
prior functional annotation and enhance the understanding
of genes with already known functions, moving a step
further in building an encyclopaedia of mammalian gene
function in the mouse.
From mutant ES cells to mouse lines
In order to carry out standardized and comprehensive
phenotyping, both the EUMODIC and the SANGER-MGP
programmes preferentially used ES cells from EUCOMM
and KOMP programmes. These programmes started in
2006 to produce mutant ES cells with a worldwide target of
16,500 mouse genes. They used standardized procedures to
generate mutant loci for genes of interest in B6 N ES cells.
This created the perfect resource for the production of
isogenic mutant lines in a standardized way and to carry
out phenotyping.
As a consequence, 83 % (665/799) of the mouse lines
were generated for the SANGER-MGP and the EUMODIC
programmes from the EUCOMM and KOMP ES cell
resources, respectively. The majority of mouse lines were
carrying the knockout first allele named ‘‘tm1a’’ in which
the transcription of a locus of interest is blocked by the
insertion of a lacZ minigene with a strong polyA sequence
just before a critical exon. A neomycin selection cassette
was found after the reporter sequence. Its expression was
driven either by the endogenous gene promoter (promot-
erless tm1a) with the b-galactosidase fused to the neomy-
cin resistance protein with a T2A cleavage site, or by a
specific promoter (promoter-driven tm1a) (Friedel et al.
2007; Skarnes et al. 2011). The tm1a allele creates a pre-
mature termination of the transcript with an interruption of
the coding sequence and in most cases is associated with
mRNA decay and the expression of the reporter gene. The
knockout first conditional ready allele is certainly very
valuable as it is possible to convert the tm1a allele to a
conditional ready tm1c allele and phenotype a lethal
embryonic gene by breeding the homozygous conditional
mouse with a cell- or tissue-specific Cre or inducible
CreERT2 line (Birling et al. 2009). Another advantage is
that the lacZ sequence from the tm1a alleles is driven by
the endogenous promoter allowing evaluation of cells that
express the targeted gene. Furthermore, the ES cell
resources were based on B6 N ES cells; this allows the
generation of mouse lines in a pure genetic background as
the chimeras were bred to that strain. More detailed
information regarding EUCOMM and KOMP clones but
also TIGM and NorCOMM mutant ES cell lines is found at
the IKMC web portal (http://www.knockoutmouse.org/
about) and in detail elsewhere (Ringwald et al. 2011).
The targeted genes from the ES cell resources were
chosen with input from the scientific community. They
were also selected because of absence of an available
(conditional) mouse line in the public domain or pheno-
typing data. Mutant ES cells were produced, validated, and
verified prior to injection at the mouse clinics. Both
phenotyping programmes were keen on evaluating and
improving the applicability of the mouse production and
phenotyping schemes. The remaining mouse models (134/
799) came from individual laboratories. They were chosen
for their scientific interest, with the commitment of their
owner to make the phenotyping data available as it became
available. They were also pilot experiments for the phe-
notyping pipelines. Interestingly, different types of alleles
were analysed, including null alleles, gene trap, ENU-
induced mutations, large-scale deletion, and transchro-
mosomic mice, underlying the general interest in the
broad-based phenotyping effort.
The mutant mouse lines were generated from the ES cell
resources using different injection strategies, using either
BALB/cN or C57BL/6Brd-Tyrc-Brd blastocyst donors, with
the aim of generating high rates of germline transmission
(GLT). The injection parameters (e.g., number of injected
cells per embryo, culture media conditions) were optimised.
A minimum of 35 % and up to 70 % of GLT was obtained in
the different centres. In order to simplify the breeding
schemes using C57BL/6 N blastocysts, it was decided that the
dominant agouti coat colour gene would be restored in the
basic JM8 cells by targeted repair of the B6 nonagouti
mutation (Pettitt et al. 2009). The EUCOMM and KOMP ES
cell resource contains different sublines of the original ES cell
line JM8 (JM8.F4, JM8.N6), with additional lines carrying
the restored agouti allele (JM8A3.N1 and JM8A1.N3). Pettitt
et al. (2009) presented a figure illustrating the coat colour of
mice and their offspring when creating mouse lines using the
different JM8 sublines. Eighty-nine percent of the mouse
lines generated from the IKMC consortium ES cells and
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phenotyped in the EUMODIC consortium originated from the
nonagouti B6 N ES cells. In total, 665 mouse lines were
generated from the mutant ES cell resources. At the ICS,
germline transmission was achieved, with a median time for
the age of the mouse chimera of 109 days and a minimum of
65 days; 95.5 % of the GLTs were obtained by 166 days.
The tm1a allele or knockout first allele is potentially a
nonexpressed (null) form in which transcription of the
targeted gene is stopped. However, RT-qPCR performed
on different targeted mouse models showed that in some
mouse models or ES cells the polyA did not entirely stop
the transcription (data not shown). In a few cases a splicing
of the selection cassette was observed resulting in pro-
duction of a low-level wild-type transcript (data not
shown). The potential of generating a knockdown instead
of a real knockout exists, even if the incidence of detecting
a small amount of wild-type protein is not truly assessed.
As a result of this, the IMPC consortium has decided to
remove the floxed coding region prior to phenotypic
analysis of future projects (especially for promoter-
containing targeting cassettes as the promoter-driven neo-
mycin is also removed) to be sure that true knockout
models are being phenotyped.
From germline transmission to cohorts
Generating the phenotyping cohort is a critical step in the
process of phenotyping, from the scientific and welfare
perspectives. Space and costs are bottleneck issues during
the process and are affected by several components,
including cohort size, age-matching animals, control
strategy, genetic background, power of the tests, and sta-
tistical management of the data.
The genetic background strongly contributes to pheno-
typic variations with a major impact on large biological
functions in genetically engineered mice. It could affect the
expression or penetrance of a given phenotype (Champy
et al. 2008; Doetschman 2009; Fitch et al. 2003; Ramı´rez-
Solis et al. 1993; Threadgill et al. 1995). To minimize this
impact, both high-throughput phenotyping projects estab-
lished the mutations on a pure B6 N background. The direct
comparison of mutants with an appropriately matched con-
trol population of mice therefore was possible. Not only was
the background uniform, but as a consequence of the
breeding scheme, the controls and the mutants differed only
by a limited number of breeding generations (Fig. 1). These
strategies offered two advantages: first, the production of a
baseline data collection to evaluate the variance, and, sec-
ond, the facilitation of the interlaboratory comparison.
However, one pitfall of the uniform genetic background is
the potential limit on the consequences of a given mutation.
Beside the ES cell resource, both programmes analysed a
limited number of mouse lines coming from different lab-
oratories with a mixed or other background strain, and in
that particular case, littermates or appropriate inbred mice
were used as controls.
The generation of cohorts on a large scale raises con-
siderable logistical issues and has proven to be the major
rate-limiting factor for high-throughput phenotyping. The
cohort size is driven largely by the nature of the tests, and,
in order to detect a significant effect (if any exists), some
tests required a consistent age-matched cohort. Within
EUMODIC and MGP programmes, from seven to ten
mutant mice per gender had been fixed to assess the vari-
ance in phenotypes according to the power of the pheno-
typing tests. To produce such cohorts, the size of the
breeding colonies was based on (1) this age-matched
cohort requirement, (2) the reproductive strain character-
istics of the parental strain used to generate the mutant
Fig. 1 Flowchart for ES cells injection and mouse breeding strategies
for cohort production. Targeted ES cells were injected to generate
chimeric animals. After germline transmission of the mutant allele,
the heterozygous mice were bred for pedigree expansion, archiving,
distribution, and cohort production. Depending on the fertility score,
heterozygous or homozygous matings were used to generate cohorts
of animals for mouse phenotyping
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strain, and (3) the various breeding schemes used between
phenotyping centres.
All the mouse production and procedures were per-
formed according to local ethical committee guidelines.
Determination of animal welfare is intrinsically linked to
phenotype outcome; therefore, animal welfare assessments
were performed through centre-specific procedures. Nev-
ertheless, the major bottleneck was found to be expansion
of the colony, and several mouse mutant lines displayed
impaired viability and fertility. Thus, embryonic or peri-
natal lethality and fertility were assessed as part of the
overall phenotypic analysis during mouse production. Data
were recorded first for the viability of homozygous off-
spring at weaning stage (2–4 weeks old) from heterozy-
gous intercrosses. Viability assessment was done by
genotyping a minimum of 28 offspring in order to be 95 %
confident that the probability of homozygous survival is
inferior or equal to 40 %. From these criteria, three out-
comes were possible per mutant strain: (i) embryonic or
perinatal lethality if no homozygous progeny was detected
from the 28 littermates, (ii) subviability if the number of
homozygotes detected was between 0 and 13 % of the 28
littermates from heterozygote intercrosses, and (iii) via-
bility if the number of homozygotes was above 13 %.
Unexpectedly, only 57 % of the 461 mouse mutant lines
analysed was viable based on the results of the two pro-
grammes, with 13 % subviable and 30 % showing homo-
zygous lethality (Table 2). The homozygous lethality was
strongly dependent on the tm1a subtype, with ‘‘promoter-
less’’ targeted loci displaying 60 % of lethality compared
to 28 % observed in ‘‘promoter-driven’’ mutant loci (v2 test
P = 2.5 9 10-11). In the ‘‘promoterless’’ targeted loci, the
gene should be expressed in ES cells to drive the neomycin
resistance. This correlation presumably reflects that loci
expressed in ES cells have a greater probability to control
critical embryonic processes and to induce lethality. This
percentage of lethal genes is comparable to that observed in
different chemical mutagenesis screens (Boles et al. 2009;
Ching et al. 2010; Hentges et al. 2006; Kile et al. 2003;
Stottmann and Beier 2010; Stottmann et al. 2011). The
lethal lines and some subviable lines were further pheno-
typed as heterozygotes.
Fertility of homozygous genetically altered mouse lines
was assessed by mating at least two sexually mature mice
from both genders. A mutant line was recorded as fertile
using homozygous intercrosses, when offspring are gen-
erated regardless of the viability of the offspring. If fertility
is uncertain in homozygous intercrosses, homozygous
mutant mice are mated to nonhomozygous mice (either
heterozygotes or wild types; Fig. 1). From this basic fer-
tility assessment, mutant lines are recorded as (1) ‘‘gener-
ates offspring’’ if pups are produced or (2) ‘‘abnormal
fertility’’ if no living pups are generated. Fertility assess-
ment was also done on heterozygotes for lethal lines and
labelled male, female, or both. The third outcome, not
applicable (N/A), is recorded for particular classes such as
imprinted genes and homozygous lethal lines. Current data
indicate that overall 7 % of the mutant lines (23 of 330
tested) showed abnormal fertility.
The production of full-size cohorts was thus often the
result of a compromise by finding particular homozygous
mutants with impaired fertility or viability and also by
centre-specific logistic constraints. As a consequence,
partial-sized cohorts (on average, 3 cohorts per line) were
often passed through each pipeline to reach the minimum
number per gender (7 mice). Figure 1 summarizes the
workflow used by the centres to optimize the mouse pro-
duction for the phenotyping pipeline, which balanced the
cohort size production requirement, the viability and fertility
phenotype annotations, and mouse distribution. All the
mutant models were archived and made available for the
scientific community through the European Mouse Mutant
Archive (EMMA) repository (Wilkinson et al. 2010) and
KOMP repositories or directly from the SANGER-MGP.
From mouse to phenotypes
The aim of the two phenotyping programmes was to per-
form a comprehensive phenotyping workflow to generate
data covering most body systems, physiology, and behav-
iour. The EUMODIC and SANGER-MGP programmes
were set up independently to carry out a comprehensive
analysis and a screen of mouse mutant lines, respectively.
The EUMODIC programme used the SOPs developed
within the EUMORPHIA consortium (www.eumorphia.org
; Brown et al. 2005). It was shaped around two independent
pipelines: the first one was devoted to morphology,
metabolism, and skeletal and cardiovascular systems, while
the second was oriented toward neurobehavioural and
sensory systems, haematology, biochemistry, and baseline
immune responses (Eumodic consortium, unpublished).
The analysis began at age 9 weeks and was completed by
15 weeks of age. Its design was based on the use of two
Table 2 Viability ratio in the mutant mouse lines studied during the
EUMODIC and SANGER-MGP programmes
tm1a subtype Lethal Subviable Viable Total % Lethal
lines
Promoter-driven 45 22 175 242 28
Promoterless 94 37 88 219 60
Total 139 59 263 461 43
% lines 30 13 57 100
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separate cohorts of mice, each composed of at least seven
mutants of each gender, to detect differences in physiology
or diseases, recognising that gender may have a consider-
able impact upon disease prevalence. It was also recom-
mended that control mice be analysed through the
phenotyping pipelines at the same time as mutants. Usually
C57BL/6 N mice have been used. Mice should be born
within a timeframe of 7–10 days. The phenotyping assays
that have been chosen for the EMPReSSslim [European
Mouse Phenotyping Resource of Standardised Screens
(EMPReSS) Slim] workflow are limited, but robust, pro-
viding a relatively broad-based first pass phenotype
assessment, both high-throughput and cost-effective. All
SOPs are available on the EuroPhenome web site and are
based on the EUMORPHIA programme (Brown et al.
2005, 2009; Morgan et al. 2010). In total, two cohorts of at
least seven males and seven females were analysed through
the 20 platforms of pipelines 1 and 2 (Table 3), and 413
phenotyping variables and 146 environmental or experi-
mental metadata were recorded (Table 4).
The SANGER-MGP pipeline was designed as a single
pipeline starting at 5 weeks of age with a high-fat diet
challenge, and followed by a battery of tests from week 4
to 16, as shown in Fig. 2 and Table 3. The pipeline was
designed to identify a variety of models from obesity to
dysmorphology with a series of 13 wide-ranging platform
tests, and record a number of variables for phenotypic
assessment as well as additional metadata impacting con-
ditions or equipment. Groups of mutant animals (up to 7
males and 7 females per line) went through as they were
produced, along with one control cohort each week for
each genetic background. The pipeline was further enri-
ched by additional procedures devoted to specific functions
such as a challenge for immune or auditory brainstem
response measurements that could be analysed during the
pipeline or with a new batch of mutant cohorts (Table 5).
The two phenotyping programmes focused on basic
physiological aspects, with platforms operating with nearly
identical or similar procedures for 11 and slightly different
ones for 8 (Table 3) with a set of common variables and
metadata. Statistical analyses have been set up based on the
way cohorts and controls were produced to ensure the use
of appropriate tests to detect the phenodeviants when they
exist. Two main approaches were applied: (1) classical
inferential statistics based on the use of large baseline
control sets, and (2) for the partial phenotyping group, the
reference range approach was preferred, using the baseline
data collection which ensured a simple and robust strategy.
The reference range approach was preferentially used by
the SANGER-MGP approach irrespective of the cohort
size. The analysis of data also helped to refine the tests and
to reduce the number of animals used in the cohorts (Karp
et al. 2010).
Even though the precise timing and the local organiza-
tion of the workflow varied, and differences between
platforms exist between the two phenotyping programmes
and the four centres involved, the efficiency of the plat-
forms in detecting phenotype is quite similar (Eumodic
consortium, unpublished). Both phenotyping pipelines
were successful in identifying phenotypes in mutants for
genes for which there was phenotyping annotation for at
least one allele already available. Sixteen of 30 mutants
analysed in the EUMODIC programme displayed phe-
notyping overlaps to annotations found in the Mouse
Genome Informatics database (http://www.informatics.jax.
org/) (Eumodic consortium, unpublished).
Taking into account the fertility and viability annota-
tions, both programmes revealed at least one phenotype in
about 83.8 % (EuroPhenome) and 76.5 % (SANGER-
MGP) of the mutant lines, demonstrating the power of
comprehensive phenotyping in defining functions for any
gene of interest. A few additional platform screens were
stopped or abandoned in the SANGER-MGP programme
and replaced with new tests (Table 5). With this new panel
of tests, the SANGER-MGP programme increased the
coverage in phenotyping particular aspects not detailed
within the common shared platforms. Where homozygote
mutants were not viable, both programmes have analysed
heterozygotes. Accordingly, the EUMODIC programme
had a phenotypic hit rate of 71.7 % in this class, under-
lining the potential for the annotation of genes through
heterozygote analysis.
Future perspectives
In conclusion, the main objective of the two efforts was
achieved with the generation of nearly 800 mouse models,
which are available and accompanied by a broad-based
phenotype analysis. Furthermore, both programmes reach
similar conclusions on mutant lethality, finding that around
30 % of mouse mutants are not viable. Both programmes
highlighted the efficiency of the broad-based phenotyping
approaches, identifying at least one phenotype in around
80 % of the mouse mutants. The mouse clinics have pro-
vided a new set of data on gene function to the scientific
community while improving the throughput and reducing
the cost of the analysis. The results summarized here
provide many logistical, operational, and scientific lessons
that will be vital as we begin the next step in undertaking a
global project of exploration of the function of genes and
generation of an encyclopaedia of the mammalian genome
by the IMPC.
Nevertheless, additional resources are required, most
importantly the completion of the project of generating
mutant ES cells for all loci in the mouse genomes: not all
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the genes are available yet in the IKMC. New initiatives
have already begun with three new programmes—The
EUCOMM-Tools for Functional Annotation of the Mouse
Genome (EUCOMMTools), the Knockout Mouse
Phenotyping Programme (KOMP2), and Norcommt2ls—to
generate a final series of mutant ES cells, along with a new
set of genetic tools for conditional genetics. Since 2011,
miR knockout (KO) ES cells are also available on the
Table 3 Phenotyping platforms used in the EUMODIC and WTSI-MGP programmes
Pipeline Procedure Age No. of parameters Important metadata
EUMODIC Pipeline 1 Dysmorphology 9 181 NA
Noninvasive blood pressure 11 3 Equipment
Calorimetry 12 10 Equipment
Simplified IPGTT 13 3 Type of strip
DEXA 14 10 Equipment
X-ray 14 31 NA
Fasted clinical chemistry 15 5 Equipment, fasting, blood collection,
sample status, anaesthesia
Heart weight 15 2 NA
EUMODIC Pipeline 2 Open field 9 18 Equipment
Surface area
Modified SHIRPA 9 21 NA
Grip strength 9 7 Equipment
Grid model
Rotarod 10 4 Equipment
Diameter of the rod
Acoustic startle and PPI 11 16 Equipment
Prepulse-pulse interval
Hot plate 12 3 NA
Indirect ophthalmoscopy 13 16 Topical agent(s)
Slit lamp 13 15 NA
Unfasted clinical chemistry 13 27 Equipment, fasting, blood collection,
sample status, anaesthesia
Haematology 13 8
FACS analysis 13 10
WTSI-MGP pipeline Open field 9 16 Equipment
surface area
Modified SHIRPA 9 21 NA
Grip strength 9 6 Equipment
Grid model
Hot plate 10 1 Light intensity, equipment
Dysmorphology 10 30 NA
Indirect calorimetry 12 9 Equipment
IPGTT 13 2 Type of strip
DEXA 14 7 Equipment
X-ray 14 41 NA
Slit lamp 15 14 NA
Ophthalmoscope 15 14 Topical agent(s)
Haematology 16 10 Equipment, fasting, blood collection,
sample status, anaesthesia
Unfasted clinical chemistry 16 26
Heart dissection 16 1 NA
FACS 16 12
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IKMC web site. Prosser et al. (2011) have developed a
resource of vectors and ES cells for targeted deletion of
microRNAs in mice and show how to generate, using
Recombinase Mediated Cassette Exchange (RMCE) from
this miR KO allele, a reporter of the miR promoter activity,
the conditional KO, and how to mutate one or other miR
organised within the miR clusters. Further resources will be
needed for long noncoding RNAs, for point mutations, and
for copy number variants, and more generally to decipher
the regulatory mechanism of the transcriptional and gen-
ome organisation. In addition, it will be important to con-
sider routes to explore heterozygous lethal or haploinsufficient
mutations that escape current analyses.
In the two programmes discussed, the mutants generated
so far and analysed were almost all derived from one allele,
the tm1a allele. A limitation of this approach is the efficient
transcription stop due to the presence of the polyA. We know
from a series of experiments in the different clinics that some
tm1a alleles do not lead to full expected inactivation of the
targeted gene. One way to circumvent the problem is to use
the tm1b allele carrying the deletion of the critical
exon(s) without the removal of the lacZ sequence (or the
lacZ and neo sequences in the promoterless mutants).
To obtain such a tm1b allele, different universal deleters are
available, but some deleters are likely to be preferred. For
example, the Gt(ROSA)26Sortm1(ACTB-cre,-EGFP)Ics deleter
eliminates one generation of breeding due to the maternal
accumulation of the Cre in the oocytes allowing the accu-
mulation of the recombinase during oogenesis and the direct
recovery of individuals carrying the deletion without the Cre
transgene (Birling et al. 2011). In addition, the line was
developed on a pure C57BL/6 N genetic background and the
presence of the transgene can be genotyped by GFP
fluorescence.
The main outcomes of the first set of mutants that were
analysed are the high level of homozygote lethality observed
with over 30 % of the lines studied and the high level of
phenotype annotations associated with heterozygous
mutants. Nevertheless, a number of additional approaches
should be considered. First, the lacZ pattern of the mutant
allele should be explored. The use of tm1a or tm1b allele’s
lacZ reporter enables us to study the expression of the gene
with good sensitivity in heterozygotes. Of course, an
inconvenience of this strategy is that regulatory elements or
other genomic elements (e.g., ncRNA, miRNA) in the intron
of the gene are modified as well. In addition, the locus might
Table 4 Lines with at least one phenotype detected in the different paradigms of the EUMODIC and WTSI-MGP programmes
EUMODIC tests and parameters Lines with phenotypes/tested SOP WTSI-MGP tests and parameters Lines with phenotypes/tested
Acoustic startle and PPI 53/313 Different Prepulse inhibition 0/2
Body weight 59/313 Different Weight curves 27/278
Calorimetry 57/313 Identical Indirect calorimetry 19/278
Clinical chemistry 112/313 Identical Plasma chemistry 54/308
Fasted clinical chemistry 57/313
DEXA 62/313 Similar Body composition (DEXA) 34/284
Dysmorphology 19/313 Similar Dysmorphology 12/287
FACS analysis 56/313 Different Peripheral blood lymphocytes 33/304
Grip strength 57/313 Similar Grip strength 7/287
Haematology 90/313 Identical Haematology (CBC) 27/308
Heart weight/tibia length 26/313 Identical Heart weight 4/309
Hot plate 14/313 Identical Hot plate 4/305
Immunoglobulin 8/313 Different Plasma immunoglobulins 6/5
Indirect ophthalmoscopy 12/313 Different Eye morphology (includes slit
lamp and ophthalmoscopy)
12/278
Slit lamp 18/313
Modified SHIRPA 59 / 313 Identical Modified SHIRPA 11/287
Noninvasive blood pressure 22/313 Different Noninvasive blood pressure 1/1
Open field 45/313 Different Open field 122/265
Rotarod 8/313 Different
Simplified IPGTT 20/313 Identical Glucose tolerance (ip) 13/276
X-ray 18/313 Identical X-ray Imaging 30/282
No phenotype detected 133/313 No phenotype detected (lines with
complete data set)
159/282
The similarity of the standard operating procedure (SOP) used is indicated
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code for various isoforms with different promoters. If the
isoform expressed in the organ of interest is different from
the isoform targeted and if it uses a different (endogenous)
promoter, the lacZ will not be expressed as expected. Sec-
ond, the phenotyping pipeline should also integrate an
embryonic screen to determine key steps of embryonic
development. Some centres have already developed an
embryonic lethal screening pipeline on a limited number of
lines with some success.
The EUMODIC and SANGER-MGP programmes pio-
neered the high-throughput production and comprehensive
analysis of mice knockouts. Considerable experience has
been gained in the logistics and operation of phenotyping
pipelines that will underpin future developments in inter-
national phenotyping programmes. For example, much
information has been gathered on the effectiveness and
sensitivity of phenotyping platforms that will prove valu-
able in the design of future pipelines, including the intro-
duction of new assays to cover physiological systems.
Along with the new partners of the IMPC, a new adult
pipeline has been developed and the establishment of a
unique and high-throughput embryonic pipeline is under
discussion. As part of this process, additional assays for
immune systems, inflammation, respiration, cognition, and
behaviour have all been considered. In addition, building
the research infrastructure capacities required in Europe for
these large-scale efforts, as well as for access of individual
researchers to high-throughput phenotyping, is the task of
the pan-European Infrafrontier programme, which has been
prioritized by ESFRI (European Strategy Forum on
Research Infrastructures). Infrafrontier also secures sus-
tainable access to mouse models archived in EMMA.
Similar efforts are underway in North America and in Asia.
With these new developments, we can expect that the
upcoming large-scale phenotyping pipeline operated by the
IMPC will prove even more effective in delivering broad-
based phenotype information on a wide variety of body
systems and physiological functions.
Fig. 2 Schematic overview of
the EUMODIC and MGP
pipelines. The Sanger MGP
pipeline started at the age of
4 weeks and ended at 16 weeks
of age, whereas the EUMODIC
programme encompasses two
pipelines, 1 and 2, which started
at 9 weeks and were completed
after 7 and 6 weeks,
respectively. The phenotyping
platforms used in these
pipelines are indicated
Table 5 Additional phenotypes detected with the specific tests
integrated in the WTSI-MGP pipeline
WTSI-MGP specific tests Lines with phenotypes/tested
Auditory brainstem response 15/323
General observations 18/18
MicroCT and quantitative Faxitron 12/51
Citrobacter challenge 23/229
Salmonella challenge 10/238
Micronuclei 8/197
Stress-induced hyperthermia 3/282
Tail epidermis whole mount 4/40
Eye histopathology 3/80
Skin histopathology 4/98
Brain histopathology 9/111
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